<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01081652</url>
  </required_header>
  <id_info>
    <org_study_id>IMP 25347</org_study_id>
    <nct_id>NCT01081652</nct_id>
  </id_info>
  <brief_title>A Study Using Micronised Progesterone (Crinone® 8%) in the Luteal Phase Support of Women Undergoing in Vitro Fertilisation (IVF) and Embryo Transfer (ET)</brief_title>
  <official_title>An Open, Randomized, Comparative, Phase III Study Using Micronised Progesterone (Crinone® 8%) in the Luteal Phase Support of Women Undergoing in Vitro Fertilization and Embryo Transfer (IVF/ET)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA, Darmstadt, Germany</source>
  <brief_summary>
    <textblock>
      This was an open-label, randomized, comparative, phase III study to evaluate the safety and&#xD;
      efficacy of Crinone 8% in comparison with progesterone 60 mg intramuscular (i.m.)&#xD;
      administered once a day in luteal phase support in 200 Chinese female subjects undergoing&#xD;
      IVF/ET.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was an open-label, randomized, comparative, multicentric, phase III study to evaluate&#xD;
      the safety and efficacy of Crinone 8% in comparison with progesterone 60 mg intramuscular&#xD;
      administered once a day in luteal phase support in Chinese female subjects undergoing IVF/ET.&#xD;
      The study planned to enroll 200 female subjects who underwent pituitary down-regulation as&#xD;
      per each center's normal practice prior to and during stimulation of multiple follicular&#xD;
      development. The progesterone administration was started on the day of ET. Randomisation was&#xD;
      performed on the day of ET. If pregnancy was confirmed on day 14 of the progesterone&#xD;
      administration, the progesterone was continued for another 45 days. The subjects were&#xD;
      followed up and the treatment outcome (negative pregnancy test or pregnancy) was recorded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">May 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The difference in hCG positive rate in the two arms 14 days after embryo transfer</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>The difference in pregnancy rates in the two arms 30 and 60 days after embryo transfer</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>The difference in implantation rate in the two arms 30 days after embryo transfer</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">238</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Crinone 8% group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Female subjects undergoing IVF/ET treated with Crinone 8% intravaginally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intramuscular progesterone group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Female subjects undergoing IVF/ET treated with 60 mg progesterone intramuscularly once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Micronised Progesterone</intervention_name>
    <description>Micronised progesterone administered intravaginally once daily from the day of ET. If pregnancy was confirmed on day 14 of progesterone administration, progesterone was continued for another 45 days.</description>
    <arm_group_label>Crinone 8% group</arm_group_label>
    <other_name>Crinone 8%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>Progesterone 60 mg administered intramuscular once daily from the day of ET. If pregnancy was confirmed on day 14 of progesterone administration, progesterone was continued for another 45 days.</description>
    <arm_group_label>Intramuscular progesterone group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient has given written informed consent&#xD;
&#xD;
          -  BMI &lt; 25 kg/m2&#xD;
&#xD;
          -  Age &lt; 36 years&#xD;
&#xD;
          -  &lt;3 prior ART cycles (IVF, ICSI and related procedures)&#xD;
&#xD;
          -  Infertility&#xD;
&#xD;
          -  Regular spontaneous ovulatory menstrual cycles&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Habitual abortion&#xD;
&#xD;
          -  Hydrosalpinges&#xD;
&#xD;
          -  History of past poor response to COH&#xD;
&#xD;
          -  Patients with serious arterial, lung, hepatic and renal diseases&#xD;
&#xD;
          -  Hepatic and renal impairment&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huafei Li</last_name>
    <role>Study Director</role>
    <affiliation>Serono Pharmaceutical Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University 3rd Hopistal</name>
      <address>
        <city>Beijing</city>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>March 4, 2010</study_first_submitted>
  <study_first_submitted_qc>March 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2010</study_first_posted>
  <last_update_submitted>July 30, 2014</last_update_submitted>
  <last_update_submitted_qc>July 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2014</last_update_posted>
  <responsible_party>
    <name_title>Medical Director</name_title>
    <organization>Serono Singapore, an affiliate of Merck KGaA, Darmstadt, Germany.</organization>
  </responsible_party>
  <keyword>Fertilisation, In vitro</keyword>
  <keyword>Embryo transfer</keyword>
  <keyword>progesterone</keyword>
  <keyword>Reproductive technologies, Assisted</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

